Astellas Japan Figures For Lipitor Down 30% Due To Generics
This article was originally published in PharmAsia News
Executive Summary
Astellas announced results for the financial year ending March 2013 with sales for top drug Lipitor (atorvastatin) down roughly 30% at ¥61 billion due to 10% price revisions and competition from generics.